- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01271465
Analysis of Donor Biopsy Tissue Samples at the Time of Kidney Transplant
mRNA and microRNA Profiles in Renal Transplant at the Time of Organ Reperfusion
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background:
Early post-transplant kidney function can be attributed to inherent donor characteristics, damage from storage, and perioperative events and recipients factors. The incidence of severe injury to the transplant kidneys is 10-25% in the early post-transplant period. In addition, milder forms of early transplant kidney injury can impact on long term allograft function. Severe transplant kidney injury in the immediate post-transplant period has been hypothesized to be associated with higher rates of rejection.
Hypothesis:
In the current investigation, we would like to test the hypotheses that 1) mRNA and microRNA expression of proinflammatory genes in donor tissues is a risk factor for development of early kidney transplant dysfunction and 2) early inflammatory mRNA and microRNA expression in the allograft is associated with subsequent activation of cell mediated immunity as evidenced by increased incidence of acute rejection episodes and increased expression of cell mediated immunity genes during the first year post-transplant.
Aims:
Aim 1: Test the association between proinflammatory mRNA and microRNA expression in donor samples and subsequent development of early organ dysfunction in the immediate period following transplantation.
Aim 2: Test the association of mRNA and microRNA expression of proinflammatory mediators in the transplanted organ in the immediate pre and post-reperfusion period with subsequent incidence of acute rejection and expression of genes involved in cell mediated immunity.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Weill Cornell Medical College
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Renal allograft recipients are generally in good health and many return to work by three months post-transplant.
However, they are maintained on immunosuppressive medications to maintain the function of the transplanted kidney.
Description
Inclusion Criteria:
- Males and females <80 years of age for kidney
- Recipients of single abdominal organ transplant
- Ability to provide written informed consent
- Donor blood and kidney biopsy tissues specimens are collected at the time of transplantation
Exclusion Criteria:
- Need for combined organ transplantation.
- Inability or unwillingness of a participant or legal guardian to provide written informed consent
- Clinical evidence of systemic bacterial infection in the recipient at the time of transplantation
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of early organ dysfunction, defined by standard criteria for each organ defined as the need for dialysis within 7 days after transplant and incidence of biopsy proven acute cellular rejection within 12 months of transplant
Time Frame: 7 days and 12 months, respectively
|
7 days and 12 months, respectively
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Serum Creatinine
Time Frame: 24 months
|
Correlation between proinflammatory mediators at the time of transplantation and renal function as measured by serum creatinine
|
24 months
|
|
Incidence of chronic allograft nephropathy
Time Frame: 24 months
|
Correlation between proinflammatory mediators at the time of transplantation and incidence of chronic allograft nephropathy
|
24 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Samuel Sultan, MD, Weill Cornell Medicine/Department of Surgery
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 1004010988
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.